“Her extensive expertise in the development and commercialization of cancer immunotherapies makes her the ideal leader to steer the company through its next stage of growth,” says David Hinton, Chair of the Board, ValoTx.

Marcella Origgi

Marcella Origgi joins from Johnson & Johnson Innovation and is an accomplished leader with extensive experience in immuno-oncology, precision medicine, and advanced therapy medicinal products (ATMPs), describes the company.

At Johnson & Johnson Innovation, she was responsible for sourcing and advancing external innovation opportunities across oncology, immunology, rare diseases, and ATMPs. Her role included identifying new assets, engaging in external partnerships, and policy development to drive innovation in life sciences.

Prior to J&J Innovation, she held key roles at Janssen’s Immunology Medical Affairs Department, where she supported the medical engagement, clinical feasibility, and launch strategies for therapies such as ustekinumab, guselkumab, golimumab, and sirukumab. In her role as MSL Champion for Immunology, she led a team of Medical Science Liaisons (MSLs), overseeing scientific training, local guideline advisory board coordination, and engagement with key opinion leaders (KOLs). She also contributed to regional and national medical planning, clinical trial feasibility assessments, and real-world evidence (RWE) initiatives.

“I am excited to join ValoTx at such a transformative time. I am looking forward to working with the talented team in Helsinki and Naples to drive clinical development across our expanded global footprint to advance life-changing treatments for patients worldwide,” says Marcella Origgi, Chief Executive Officer, ValoTx.